Isis Development Partner ICo Therapeutics Files IND For Antisense Drug To Treat Eye Disease

... Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that iCo Therapeutics, an Isis licensee, has filed an Investigational New Drug (IND) application with the FDA for iCo-007, for the treatment of eye diseases including age-related macular degeneration (AMD) and diabetic retinopathy (DR). Isis will receive a milestone payment from iCo based on this IND filing. [click link for full article] ...